Clinical Trial Update: An Open-label, Uncontrolled Study of ONO-4578 and ONO-4538 in Combination With Standard-of-care Docetaxel and Ramucirumab as Second-line Therapy in Patients With Advanced or Recurrent Non-small Cell Lung Cancer [Phase 1]

View source ↗

Summary

An open-label Phase 1 study evaluates ONO-4578 and ONO-4538 in combination with standard-of-care docetaxel and ramucirumab as second-line therapy for advanced o…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Non-small Cell Lung Cancer

Drugs mentioned

• DOCETAXEL (DOCETAXEL)
• ONO-4538
• ONO-4578
• Ramucirumab (ramucirumab)

Snippet

Sponsor: Ono Pharmaceutical Co., Ltd. | Conditions: Non-small Cell Lung Cancer | Phase 1 | Status: ACTIVE_NOT_RECRUITING